| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer
|
|
Vancouver, BC, November 22, 2021--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Neil Josephson, M.D., who has been serving as the company's interim Chief Medical Officer (CMO) since May of this year, will transition to the permanent CMO position, effective November 15.
|
|
|
|
|
|
|
|
|
|
Zymeworks Reports 2020 Year-End Financial Results
|
|
Vancouver, BC, March 1, 2021--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported financial results for the year ended December 31, 2020 and provided a summary of recent business and clinical highlights.
|
|
|
|
|
|
|
|
Zymeworks Expands Commercial Team and Creates New R&D Role
|
|
Vancouver, BC, February 10, 2021--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that James Priour, former Senior Vice President, Commercial, has been promoted to Chief Commercial Officer and named to the Company's Executive Committee.
|
|
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
